Upon intracranial or intravenous administration, Bcl2L12-SNAs could cross the blood-brain barrier (BBB), penetrate the glioma, and promote apoptosis of glioma cells by enhancing caspase and p53 activities. Here, BCL2L12 is linked to central nervous system cancer.